Amgen Joins Bid To Nix Alexion's Blood Drug Patent
Amgen Inc. has told a London court that its biosimilar for a patented rare blood disease treatment of Alexion does not infringe the AstraZeneca unit's protections for the drug, arguing that...To view the full article, register now.
Already a subscriber? Click here to view full article